Siolta Therapeutics picked up SymBiosis and Kirin Holdings in a round set to fund efficacy trials of its potential asthma treatment.
US-based microbe therapy developer Siolta Therapeutics has attracted $30m in a series B round involving medical services provider SymBiosis.
Kirin Health Innovation Fund, a corporate venturing vehicle for food and healthcare products group Kirin Holdings, also participated, as did Seventure’s Health for Life Capital Fund, Global Brain’s GB-VII and private investor Marc Benioff.
Spun out of University of California, San Francisco in 2016, Siolta Therapeutics hopes to uncover therapeutic microbes capable of treating chronic inflammatory diseases such as allergies.
The…
